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Open access unThe role of HPV in esophageal squamous cell carcinoma (ESCCs) is controversial. Therefore, we deter-
mined, through different methodologies, the prevalence of HPV in 264 ESCC samples from Brazil, and cor-
related it with the presence of surrogate markers and clinicopathological characteristics. HPV is present
in 13% of ESCC, and with a 3-fold variation between high and medium incidence areas. Most HPV positive
tumors were infected with HPV16, but this was not associated with p16 expression, TP53mutation status,
patient age, amount of tobacco or alcohol consumption, or overall survival. We conclude that HPV infec-
tion may not have a role in ESCC.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Esophageal cancer (EC) is one of the most common malignan-
cies worldwide, presenting a poor prognosis with a 5-year survival
rate around 10%, mainly due to late stage diagnosis. EC accounted
for 481,645 new cases and 406,533 deaths in 2008, being the 8th
most incident and the 6th most fatal type of cancer in the World
[1,2]. The vast majority of EC cases occur predominantly as squa-
mous cell carcinoma (ESCC) [1,2].
ESCC etiology is rather complex, and although numerous factors
have been associated with the disease in different parts of the
World, many of them contribute with each other to inﬂuence the
incidence rates observed [3]. In Brazil, for instance, where the high-
est incidence rates for the disease in the West are observed, ESCC
patients present in most parts of the country a typical westernos de Carcinogênese Molec-
âncer, Rua André Cavalcanti,
231-050, Brazil. Tel.: +55 21
der the Elsevier OA license.ESCC proﬁle, with alcohol consumption and tobacco smoking being
the main disease risk factors [4,5]. However, in southern Brazil,
where the incidence rates observed (18/105 men and 7/105 wo-
men) are twofold higher than in the southeastern part of the coun-
try, the consumption of hot-maté is also an important risk factor
[6,7].
Although the presence of Human Papillomavirus (HPV) in ESCC
was demonstrated in the early 1980s [8], its role in ESCC carcino-
genesis is still controversial [9]. Studies done with different popu-
lations have shown a wide variation in HPV prevalence (from 0% to
almost 100%) and subtype, which could be the result of the inter-
action with other etiological factors, and/or differences in the
methodology applied to detect it [10–12]. Furthermore, studies
that evaluated surrogate markers for HPV infection in larger num-
ber of ESCC samples are scarce, and to date there is no study which
associated HPV prevalence with TP53 mutation status.
HPV is a small double-stranded DNA virus with tropism for the
squamous epitheliumwhere it can cause hyperproliferative lesions
[13]. HPV oncoproteins such as E6 and E7 not only have roles in
viral genome replication but also interact with host cell cycle con-
trol proteins, such as p53 and pRb, inactivating them [14]. In this
S. Herbster et al. / Cancer Letters 326 (2012) 52–58 53manner, head and neck tumors (HNSCC) that are positive for
HPV16, a cancer high risk subtype, present elevated p16 expression
as a result of pRb inactivation by E7 and no TP53 inactivating muta-
tions [15–17].
Therefore, the objective of this study was to investigate the
prevalence of HPV in ESCCs from patients from the southern and
southeastern regions of Brazil, through nested PCR and in situ
hybridization. In addition, in order to determine the role of HPV
infection in ESCC carcinogenesis we correlated HPV infection with
the presence of surrogate markers such as p16 expression and TP53
mutations, as well as patients’ clinicopathological characteristics.
2. Materials and methods
2.1. Patients
Two-hundred and sixty-four tumors with a histologically conﬁrmed diagnosis
of ESCC were obtained from patients recruited between September/2000 and
July/2009 from four hospitals, being three of them situated in the southeastern
region of Brazil: Hospital Universitário Pedro Ernesto (HUPE-UERJ) and Instituto
Nacional de Câncer (INCA), both located at Rio de Janeiro, and Hospital de Clíni-
cas-Gastrocentro (HC-UNICAMP), located at Campinas, São Paulo. The fourth hospi-
tal is situated in the southern region, Hospital das Clínicas (HC-UFRGS), located at
Porto Alegre, Rio Grande do Sul. All individuals who took part in this study signed
an informed consent and information was obtained by a standardized question-
naire. Data on tobacco smoking was obtained concerning the number of cigarettes
smoked and the duration of the habit (expressed as pack/year, deﬁned as the num-
ber of packs smoked per day multiplied by the number of smoking years) and indi-
viduals were classiﬁed as never or ever-smokers (deﬁned as smoking at least one
cigarette per day and persisting for more than 1 year). Individuals were classiﬁed
regarding alcohol intake as never or ever-drinkers (deﬁned as drinking alcoholic
beverages at least twice a week and persisting for more than 1 year). Data was col-
lected regarding clinical intervention, tumor stage and differentiation, esophageal
localization, presence of a second primary head and neck tumor and whenever pos-
sible overall survival time after diagnosis. The study proposal and all ethical pro-
ceedings were approved by the Ethic Committees of the hospitals.
2.2. DNA isolation, TP53 exon 5–8 ampliﬁcation and direct sequencing
DNA was extracted from frozen and formalin ﬁxed parafﬁn embedded (FFPE)
samples by proteinase K/SDS digestion or the QIAamp DNA FFPE Tissue kit (QIAGEN,
Germany), respectively. Sections were cut at 5 lm and 15 and 25 sections were col-
lected from surgical and from biopsy material, respectively, after revision by a
pathologist to certify that only tumor cells were taken for DNA extraction. Proper
caution was taken regarding sample cross contamination, with the use of one blade
for each sample, sectioning a sample free parafﬁn block after each ﬁve samples and
the total isolation of the different procedures, such as DNA extraction, PCR reaction
and electrophoresis. Ampliﬁcation of TP53 (exons 5–8, and exon–intron boundaries)
and direct sequencing of amplicons were performed as previously described
[18,19].
2.3. HPV analysis by PCR and direct sequencing
An aliquot of the extracted DNA was quantiﬁed by reading its absorbance in a
Nanovue spectrophotometer (GE Healthcare, UK). When the ratio of optical densi-
ties, A260/A280, was equal to or greater than 1.7 the material was considered to
be pure. PCR was used to amplify the housekeeping gene b-actin (100 bp) to assess
the presence of PCR inhibitors in the samples used in this study. PCR for b-actinwas
performed using 1X PCR buffer (Invitrogen, USA), 3 mM MgCl2 (Invitrogen, USA),
0.2 mM dNTPs, 0.5 U of Platinum Taq DNA polymerase (Invitrogen, USA), 3 pmol of
each primer (Table 1), 100 ng of genomic DNA and sterile ultrapure water up to
25 lL. Nested PCR was used for the ampliﬁcation of the HPV L1 gene in all samples,
with proper negative and positive PCR controls in both ampliﬁcations. The ﬁrst PCR
round was done with the MY09/11 degenerated primer set (Table 1), whereas
GP5+/GP6+ primers (Table 1) were used for the second round [20,21]. HPV positive
controls were obtained from cervix tumor FFPE samples, with a 100% concordance
between b-actin and HPV nested PCR ampliﬁcations. We performed these reactions
using 1X PCR buffer (Invitrogen, USA), 3 mM MgCl2 (Invitrogen, USA), 0.2 mM
dNTPs, 0.5 U of Platinum Taq DNA polymerase (Invitrogen, USA), 25 pmol of each pri-
mer, 500 ng of genomic DNA and sterile ultrapure water to a ﬁnal volume of 25 lL.
DNA was ﬁrst denatured for 5 min at 94 C and 40 PCR cycles consisting of three
steps were performed: denaturation for 30 s at 92 C, annealing for 1 min at 55 C
for the ﬁrst round with the external primers and at 40 C for the second round with
the internal primers and extension for 1 min at 72 C. At the end, an additional cycle
for 10 min at 72 C was performed. PCR products were then puriﬁed with the Pure-
Link™ Genomic DNA Puriﬁcation kit according to the manufacturer’s protocol
(Invitrogen, USA).The sequencing reactions were performed with the ET Dye Terminator Cycle
Sequencing kit (GE Healthcare, UK) and the same primers used in the nested PCR
reaction (Table 1). Sequencing reactions were analyzed with the MegaBACE 1000
sequencing platform (GE Healthcare, UK). Sequences were analyzed using Chromas
software (http://www.technelysium.com.au/chromas.html).
2.4. HPV analysis by In situ Hybridization (ISH)
Seventy-six (38 HPV PCR negative and 38 HPV PCR positive samples) FFPE sam-
ples were sectioned at 10 lm and parafﬁn was removed with xylene, re-hydrated
through a graded ethanol series and ﬁnally washed in PBS. In situ hybridization
analysis was done using the Dako GenPoint tyramide signal ampliﬁcation system
for biotinylated probes exactly as described by the manufacturer (HPV wide Dako,
Dako Corporation, USA). The positive control was a cervical squamous cell carci-
noma sample, whereas the negative control was obtained by omitting the HPV
probe. The presence of a positive signal was searched throughout the entire slide.
2.5. Detection of p16 expression by immunohistochemistry
FFPE samples were sectioned (3–4 lm), placed on sillanized slides and left in an
oven at 60 C for 12 h. The expression of p16 was then analyzed by immunohisto-
chemistry using with the CINtec Histology Kit (Biogen/Roche, Germany), according
to the manufacturer’s protocol. After adding the Substrate-Chromogen Solution
(DAB) for 10 min at room temperature, slides were washed with distilled water
and stained with Harris Hematoxylin for 20 s followed by a 5 min wash with tap
water. The sections were ﬁnally dehydrated and mounted with coverslips with
ERV-MOUNT (EasyPath, Brazil).
2.6. Statistical analysis
To assess the relationship between the epidemiological and clinical data, TP53
mutations and the presence of HPV, we used the chi-square, the Fisher’s exact test
and the Student’s t test. Results were considered statistically signiﬁcant when
p < 0.05. For evaluation of the impact of HPV on overall survival probability, we ap-
plied Kaplan–Meier and the log-rank test to assess signiﬁcance of differences
among survival curves. All statistical analysis was performed with GraphPad Prism
5 (GraphPad Software, USA).3. Results
Two-hundred and sixty-four ESCC DNA samples were analyzed
for the presence of HPV by PCR, with 38 of them presenting a po-
sitive amplicon. The PCR-positive samples were further submitted
to HPV analysis through ISH, with 89% being positive. Fig. 1 shows
that the immunoreactivity signal and the number of positive cells
in ESCC are much lower than seen in the cervix carcinoma samples
(positive control). ISH positive samples showed a rather uniform
proﬁle, with less than 10% of the cells presenting a positive weak
DAB staining. We also analyzed 38 PCR negative HPV samples by
ISH, with a concordance of 100%.
Therefore, samples were considered HPV positive when they
were positive in both PCR and ISH. By this standard, an overall re-
sult of 34 (13%) HPV positive tumors were obtained. According to
patient geographical origin, 19 out of 84 (23%) tumors from south-
ern Brazil patients were HPV positive, compared to only 15 out of
180 (8%) tumors from patients from the southeastern region
(p = 0.003). HPV positive amplicons were sequenced to have the
viral subtype discriminated. We were able to obtain the subtype
identity for 31 samples (92%) and observed that HPV16 was the
most prevalent subtype, being present in 79% and in 67% of HPV
positive ESCCs from the southern and southeastern regions,
respectively. HPV66 was present in 33% of the southeastern region
patients, whereas HPV18 was present in one patient (5%) from the
southern region. Due to limitations in sample quantity and viral
load we did not succeed in identifying the HPV subtype from three
southern region patients.
TP53 mutations were analyzed in 166 of the 264 ESCC samples
(63%), including 32 of the 34 (94%) HPV positive tumors. We
identiﬁed 53 mutations present in 50 tumors (30% of mutation fre-
quency) since three ESCCs presented double TP53 mutations.
Among these mutations, 68% were missense (all resulting in loss
Table 1
PCR conditions: ampliﬁed regions, speciﬁc primers and the size of the ampliﬁed products.
Gene Primer Primer pairs (50 ? 30) Product size (bp) Ref.
Exon 1st round-Fa F: TGTTCACTTGTGCCCTGACT 310 [19]
TP53 1st round-Rb R: AGCAATCAGTGAGGAATCAG
Exon 5 2nd round-F F: TTCAACTCTGTCTCCTTCCT 248
2nd round-R R: CAGCCCTGTCGTCTCTCCAG
TP53 1st round-F F: TGGTTGCCCAGGGTCCCCAG 224 [19]
Exon 6 1st round-R R: TGGAGGGCCACTGACAACCA
2nd round-F F: GCCTCTGATTCCTCACTGAT 181
2nd round-R R: TTAACCCCTCCTCCCAGAGA
TP53 1st round-F F: CTTGCCACAGGTCTCCCCAA 237 [19]
Exon 7 1st round-R R: AGGGGTCAGCGGCAAGCAGA
2nd round-F F: AGGCGCACTGGCCTCATCTT 177
2nd round-R R: TGTGCAGGGTGGCAAGTGGC
TP53 1st round-F F: TTGGGAGTAGATGGAGCCT 313 [19]
Exon 8 1st round-R R: AGAGGCAAGGAAAGGTGATA
2nd round-F 2nd round-R F: TTCCTTACTGCCTCTTGCTT 231
R: AGGCATAACTGCACCCTTGG
b-Actin – F: GATGAGATTGGCATGGCTTT 100 Designed by the authors
R: CACCTTCACCGTTCCAGTTT
HPV MY 09 CGTCC[A/C]A[A/G][A/G]GGA[A/T]ACTGA TC 450 [20]
MY 11 GC[A/C]CAGGG[A/T]CATAA[T/C]AATGG 450
GP5+ TTTGTTACTGTGGTAGATACTAC 150 [20]
GP6+ GAAAAATAAACTGTAAATCATATTC 150
F: forward; R: reverse; bp: base pairs.
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sense, 4% were at splicing sites and only 2% were silent. Table 2
shows that there was no association between the presence of
HPV and TP53 mutations, with the frequency of TP53 mutations
being 33% (44 out of 134) and 28% (nine out of 32) in HPV negative
and positive ESCCs, respectively (p = 0.68). Fig. 2 shows the expres-
sion of p16 analyzed by immunohistochemistry. P16 positive
staining pattern was diffuse, localized in both cytosol and nucleus
with a moderate to strong intensity and was present in the entire
tumor. P16 expression was observed in 20% (seven out of 34) of
HPV positive and in 10% (three out of 30) of HPV negative ESCCs.
The presence of HPV was analyzed regarding the patients‘ clin-
icopathological parameters, as shown in Table 3. The mean age of
HPV positive and negative ESCC patients was not different. HPV po-
sitive tumors presented a higher frequency in the distal part (nine
out of 23, 39%), and a lower frequency in the proximal part of the
esophagus (two out of 23, 9%), when compared to HPV negative
ESCCs (33 out of 167, 17%; and 49 out of 167, 25%, respectively,
p = 0.01). There was a slight lower consumption of tobacco and
lower percentage of alcohol drinkers among HPV positive ESCC pa-
tients, but this was not statistically signiﬁcant (p = 0.091). Simi-
larly, HPV positive ESCCs were more frequent in patients who
did not have a second primary head and neck cancer, but this
was also not statically signiﬁcant (p = 0.34). Fig. 3 shows that the
presence of HPV did not alter ESCC prognosis, with the median
overall survival time for HPV positive and negative ESCC patients
being 7.5 and 8.5 months, respectively (p = 1.0).4. Discussion
In this work we demonstrated, through L1-GP5+/GP6+ nested
PCR ampliﬁcation with direct sequencing and ISH, that HPV is pres-
ent in 13% of ESCCs from Brazil, but with a 3-fold variation be-
tween patients from the high and medium incidence areas of the
disease. Although the vast majority of HPV positive tumors pre-
sented infection with the high risk HPV16 subtype (74%), HPV po-
sitive tumors were not associated with p16 expression, absence or
lower frequency of TP53 mutations, lower patient age, lower fre-
quency of tobacco or alcohol consumption, nor did it alter overall
survival.Although HPV was detected almost 30 years ago in condiloma-
like lesions and in ESCCs [4], the role of HPV in esophageal carcino-
genesis is still not established. Reasons for this include the wide
variation in HPV positive frequency and subtype observed in ESCCs
from different populations [21–23]. This variation may be real or a
result of the different methodologies employed and the low num-
ber of samples analyzed in most studies [24–26]. For instance, two
studies carried out in ESCC of Chinese patients using either PCR
based methodology or ISH detected an HPV prevalence of 17% of
117 patients [27], and 77% of 106 patients [23].
Two of the most widely used methods to detect HPV are PCR
and ISH, which had never been used simultaneously for HPV detec-
tion in ESCCs. PCR based methodologies present different sensitiv-
ities and speciﬁcities, due to variation in the method used and/or
sample cross contamination [11,28]. Alternatively, the chromo-
genic ISH assay has been widely used to detected HPV presence
in different tumors, albeit being less sensitive than PCR [29]. In this
regard, the use of both methodologies simultaneously can help to
avoid possible under or over detection of HPV in FFPE samples.
Although we used b-actin ampliﬁcation as an internal control to
detect possible PCR inhibitors in the reactions, the expected ampli-
con produced (100 bp) is signiﬁcantly shorter than the HPV ampli-
con produced by the ﬁrst round PCR reaction employed in this
study (Table 1), which could lead to a potential underdetection
of HPV positive tumors. However, not only we obtained a 100% cor-
relation between PCR and ISH on negative HPV results, but also we
obtained a similar percentage of HPV positive samples between all
of the tumors and those that had exons 5–8 of the TP53 gene
ampliﬁed. Therefore, if there were any false negative cases in our
study, these were kept to a minimum frequency. The correlation
of positive HPV detection between PCR and ISH was 89%, which
is very similar to that seen for head and neck tumors [17].
We were able to unequivocally show a threefold variation in
HPV prevalence among ESCCs of patients from high (southern Bra-
zil) and medium (southeastern Brazil) incidence areas. We do not
know at the moment the reason for such variation, but are tempted
to speculate that an important risk factor for ESCC present only in
southern Brazil, the consumption of hot-maté and the resulting
esophageal thermal lesion [15,18], may facilitate HPV infection in
the esophagus of patients from that region. A previous study car-
ried out with 165 patients from southern Brazil that analyzed
Fig. 1. Representative pictures of the speciﬁc staining obtained by ISH to detect HPV DNA (brown spots in FFPE samples). (a and b) ESCC negative samples. (c and d) cervical
carcinoma used as positive control for HPV speciﬁc staining. (e–h): speciﬁc staining observed in two ESCC samples as indicated by the red arrows. A, C, E and G were obtained
with a 60magniﬁcation, while b, d, f and h were obtained with a 100magniﬁcation. ISH, In situ hybridization; ESCC, esophageal squamous cell carcinoma; FFPE, Formalin-
Fixed, Parafﬁn-Embedded.
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all of them being HPV16 [30].
Most of the studies that used PCR identiﬁed HPV16 as the main
HPV subtype present in ESCC from different populations. However,a number of other high and also low risk HPV subtypes have been
identiﬁed in ESCCs, such as HPV18, HPV11, HPV33, and HPV31,
among others [21–24]. In our study, HPV16 was the most prevalent
subtype found in ESCC (74%), followed by HPV66 (15%), and HPV18
Table 2
Frequency of TP53 mutations in HPV positive and negative esophageal squamous cell
carcinoma samples.
Wild TP53 n (%) Mutated TP53 n (%) p Value
Total n = 166
HPV negative 90 (69.2%) 44 (32.8%) 0.6774
HPV positive 23 (71.9%) 9 (28.1%)
Fisher exact test. Differences were considered signiﬁcant when the value of p < 0.05.
56 S. Herbster et al. / Cancer Letters 326 (2012) 52–58(3%). There was no difference between HPV16 prevalence between
ESCCs of patients from the southern and southeastern parts of
Brazil, but HPV66 was detected only in patients from the south-
eastern region, suggesting that rare high risk subtypes may infect
a small percentage of ESCC patients in determined geographical
areas.Fig. 2. Expression of p16 in either HPV positive or negative ESCCs. (a and b) HPV positi
10).
Table 3
Association between clinicopathological parameters and the presence of HPV in esophage
HPV positive (n = 34)
Epidemiological data
Age (mean ± SD) 60.31 ± 9.92
Gender
Men 20 (74.1%)
Women 7 (25.9%)
Alcohol consumption
Never 6 (25.0%)
Ever 18 (75,0%)
Tobacco consumption
Never 2 (7.7%)
Ever 24 (92.3%)
Mean consumption (packs/years) 35
Clinical data
Tumor location
Proximal esophagus 2 (8.7%)
Middle esophagus 12 (52.2%)
Distal esophagus 9 (39.1%)
Tumor differentiation
Well and moderately 13 (76.5%)
Poorly 4 (23.5%)
Tumor stage
I–II 1 (8.3%)
III–IV 11 (91.7%)
Diagnosis of primary tumor in head and neck site
No 13 (86.7%)
Yes 2 (13.3%)
Overall survival
>12 Months 3 (25.0%)
<12 Months 9 (75.0%)
The statistical test used in tumor location data analysis was Chi-square test, whereas the
exact test was applied to the other variables. Differences were considered signiﬁcant wHPV exhibit a main role in a signiﬁcant number of oropharynx
tumors, which affects not only the clinicopathological characteris-
tics of patients but also the molecular alterations present in those
tumors [17,31]. So, HPV positive oropharynx cancer patients are
typically younger, do not present a history of tobacco smoking or
alcohol drinking, possess higher socioeconomic status and better
prognosis when compared with HPV negative tumor patients
[32–35]. Furthermore, HPV positive tumors present high p16
expression, as a result of pRb inactivation by E7 and a lack of
TP53 mutations due to the effect of E6 on p53 [15,16]. However,
the precise role of HPV in oral tumors is still controversial
[36,37]. For instance, a recent study done with 114 Brazilian pa-
tients showed that HPV positive oral tumors present high p16
expression and are more frequent in younger patients. However,
there was no difference between HPV positive and negative oralve samples (scale bars 50 lm – 20). (c) HPV negative sample (scale bar 100 lm –
al squamous cell carcinoma samples.
HPV negative (n = 230) p Value
58.85 ± 10.05
164 (78.5%) 0.62
45 (21.5%)
22 (10.8%) 0.091
181 (89.2%)
18 (8.8%) 1.0
187 (91.2%)
40
49 (24.5%) 0.018
118 (59.0%)
33 (16.5%)
118 (73.8%) 1.0
42 (26.2%)
13 (11.3%) 1.0
102 (88.7%)
52 (73.2%) 0.34
19 (27.5%)
27 (27.6%)
71 (72.4%)
Student’s t test was used to evaluate the variables age and overall survival. Fisher’s
hen the value of p < 0.05.
Fig. 3. Kaplan–Meier overall survival curve. ESCC patients overall 5 year survival
curve according to HPV status. HPV negative individuals are represented in gray and
HPV positive individuals in black. HR: hazard ratio; CI: conﬁdence interval.
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our study, we also did not detect any difference between tobacco
and alcohol consumption, or overall survival probability between
HPV positive and negative ESCC patients. Three previous studies
also fail to show a difference in overall survival rates between
HPV positive and negative ESCCs [38–40]. However, differently
from oropharynx and oral tumors [37,41,42], we found no differ-
ence in p16 expression, TP53 mutation frequencies, or patient age
between HPV positive and negative ESCCs. TP53 mutations have
been considered the earliest genetic alterations during esophageal
squamous neoplastic transformation [43]. Although HPV has also
been reported to be present in preneoplastic lesions such as dys-
plasias [44], our results suggest that either HPV infection in the
esophageal mucosa of most patients occur after TP53 mutations
or that HPV is not integrated into the host genome and, therefore,
E6 and E7 would not be playing their roles during neoplastic trans-
formation. However, we did not analyze E6 and E7 expression
since there was not enough material available, preventing us to
reach a conclusion in this regard.
Two recent studies that analyzed HPV prevalence in over 200
patients and used p16 expression as a surrogate marker showed
an overall low prevalence of HPV in ESCCs. Koshiol and Kreimer
[45] showed that two out of 267 Chinese patients presented high
risk HPV positive tumors but did not express p16, concluding that
HPV is not associated with ESCC in Chinese patients. Antonsson
et al. [39] showed that only eight out of 222 Australian patients
were HPV positive, with half expressing p16, and that there was
no correlation between the presence of HPV and tobacco or alcohol
consumption.
We conclude that the prevalence of HPV in ESCCs from high and
medium incidence populations in Brazil is different and, although
HPV16 is the main HPV subtype to infect ESCC of Brazilian patients,
the role of HPV in ESCC carcinogenesis in these populations is
questionable since it does not alter HPV associated surrogate
markers or patients’ clinicopathological parameters.Acknowledgments
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